Psyence Biomedical (PBM) Regains Nasdaq Compliance

Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that it has received formal notification from the Nasdaq Hearings Panel confirming that the Company has regained compliance with all applicable Nasdaq continued listing requirements. This confirmation follows a successful compliance hearing held on May 29, 2025.

"As a result of the decisive steps we've taken, Psyence BioMed is now fully compliant with Nasdaq's continued listing standards," said Dr. Neil Maresky, Chief Executive Officer of Psyence BioMed. "With a debt-free balance sheet, strong cash position, and a focused strategy, we believe we are well positioned to accelerate the commercialization of our nature-derived therapeutics and advance our mission to deliver evidence-based solutions – using psilocybin and Ibogaine – for unmet needs in palliative care, addiction, and related mental health conditions."

To support its efforts to regain compliance, the Company's shareholders approved a share consolidation (reverse stock split) at a Special Meeting of Stockholders held on April 16, 2025. The approved proposal authorized a reverse split at a ratio of up to 1-for-50, or a lesser amount at the discretion of the Board of Directors. The Board subsequently approved a final ratio of 1-for-7.97, which was implemented to increase the per-share trading price of the Company's common shares to meet Nasdaq's $1.00 minimum bid price requirement under Listing Rule 5550(a)(2).

"We appreciate the opportunity provided by the Nasdaq Hearings Panel to demonstrate our full compliance," added Dr. Maresky. "This reaffirms our commitment to strong corporate governance and long-term value creation for our shareholders."

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Real and RE/MAX Holdings receive court approval for merger
• Knorex discloses going concern note in annual report